← Back to screener

Indivior Pharmaceuticals, Inc. INDV

Rank #1545 · Nasdaq · $4.3B market cap
Audited by PricewaterhouseCoopers LLP, no going-concern flag in the latest filing.
Score
46.5
P/E
-34.2
P/B
-287.49
ROE
840.0%
Op. Margin
-13.9%
Debt Ratio
-12947%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Poor

P/E -34.2x, P/B -287.49x. Ranks in the top 86% of the universe.

Profitability ★★★☆☆
Good

ROE 840.0%. Ranks in the top 40% of the universe.

Safety ★★★★★
Excellent

Debt ratio -12947%. Ranks in the top 0% of the universe. Under 100% is generally considered a safe level.

Growth ★★★★☆
Excellent

Revenue growth of 21.3% year over year. Ranks in the top 17% of the universe.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2024$0.9B$-0.1B$-0.0B$0.1B-9.01612
2025$1.1B$-0.2B$-0.1B$-0.0B-13.9-12947

← See the full screener